R&D Trends

Embera wins $11M NIDA grant for cocaine addiction treatment EMB-001

Wednesday, July 27, 2016

Embera NeuroTherapeutics, a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the NIH. The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”

[Read More]

Wiley launches Wiley Spectra Lab

Tuesday, July 26, 2016

Wiley has launched Wiley Spectra Lab, a new and flexible expert spectral data system that uses empirical data and advanced software to help chemists, toxicologists, and life scientists confidently identify chemical substances. Wiley Spectra Lab provides access to these data in a convenient, secure cloud environment.

[Read More]

AbbVie, Bristol-Myers Squibb ink oncology clinical collaboration

Tuesday, July 26, 2016

AbbVie and Bristol-Myers Squibb have announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC).

[Read More]

Study: Mentorship programs build long-term research careers

Tuesday, July 19, 2016

A public-private mentored research program based at the NIH called the NIH Clinical Research Training Program (CRTP) has helped foster the careers of research-oriented medical and dental students, and similar programs may help bolster the dwindling pipeline of biomedical researchers and clinician-scientists, according to a study now available electronically in Academic Medicine.

[Read More]

NIH expands investment in HIV cure research

Tuesday, July 19, 2016

The NIH has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research. The research program is supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse, the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, all part of the NIH.

[Read More]

Boehringer Ingelheim, University of Dundee collaborate to develop new class of medicines

Tuesday, July 19, 2016

Boehringer Ingelheim and the University of Dundee will join forces in an exciting collaboration with the aim to develop a novel class of medicines that target disease causing proteins for degradation. The collaboration brings together the expertise of Dr Alessio Ciulli, one of the pioneers in the field of PROTACs and based in the School of Life Sciences at Dundee, with Boehringer Ingelheim’s expertise in drug discovery and clinical development of new therapeutic agents.

[Read More]

NCI, CRUK, Wellcome partner on cancer models to accelerate research

Monday, July 11, 2016

An international project to develop a large, globally accessible bank of new cancer cell culture models for the research community has launched. The National Cancer Institute (NCI), part of the NIH; Cancer Research U.K., London; the Wellcome Trust Sanger Institute, Cambridge, England; and the foundation Hubrecht Organoid Technology, Utrecht, Netherlands, are joining forces to develop the Human Cancer Models Initiative (HCMI), which will bring together expertise from around the world to make about 1,000 cancer cell models.

[Read More]